Pharmaceutical preparations for treatment of estrogen deficiency in the central nervous system
    2.
    发明授权
    Pharmaceutical preparations for treatment of estrogen deficiency in the central nervous system 失效
    用于治疗中枢神经系统雌激素缺乏症的药物制剂

    公开(公告)号:US06245756B1

    公开(公告)日:2001-06-12

    申请号:US09252726

    申请日:1999-02-19

    IPC分类号: A61K31566

    CPC分类号: A61K31/567 A61K31/565

    摘要: Pharmaceutical preparations containing selected steroid compounds and methods of treating estrogen deficiency in the central nervous system (CNS) without influencing other organs or systems are described. These steroids have selective neurotropic estrogen-like transcription action in contrast to the systemically acting natural and synthetic estrogen compounds, such as 17&agr;-estradiol. The selected steroids surprisingly have a selective influence on the transcription estrogen-dependent gene in the CNS and cause changes of physiological parameters as well as CNS-specific transcription effects in the dosages used with no biological effects in reproductive system tissues. They have CNS specific transcription effects at those dosages at which neither 17 &bgr;-estradiol nor 17&agr;-estradiol had any action and the transcription estrogen-dependent gene in the CNS is not influenced by secondarily formed 17&bgr;-estradiol.

    摘要翻译: 描述了含有选择的类固醇化合物的药物制剂和治疗中枢神经系统(CNS)中雌激素缺乏症的方法,而不影响其他器官或系统。 与系统作用的天然和合成雌激素化合物(如17α-雌二醇)相比,这些类固醇具有选择性神经营养因子雌激素样转录作用。 所选择的类固醇令人惊奇地对CNS中的转录雌激素依赖性基因具有选择性影响,并且在生殖系统组织中没有生物效应的剂量中引起生理参数的变化以及CNS特异性转录效应。 它们在17β-雌二醇和17α-雌二醇都不具有任何作用的那些剂量下具有CNS特异性转录效应,并且CNS中的转录雌激素依赖性基因不受二次形成的17β-雌二醇的影响。